Drug Trial Radar · NCT05991583
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Jul 3, 2023
Primary completion
Nov 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.
Conditions
- Advanced Malignant Tumors
Interventions
IBB0979Drug
IBB0979 should be subcutaneous injected,qw
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse events (AEs) and SAEs (Phase Ⅰ)Time frame: 3 months after end event visit
- Dose limiting toxicities (DLTs) (Phase Ⅰ)Time frame: 21 days after first dose
- Objective response rate (ORR) in dose expansion (Phase Ⅱa)Time frame: Baseline through up to 1 years or until disease progression
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.